A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


The history of biomarkers and ultrasonography dates back over more than 50 years. The present status of biomarkers used in the context of ovarian cancer is addressed. Attention is given to new interpretations of the etiology of ovarian cancer. Cancer antigen 125 (CA125) and multivariate index assays (Ova1, Risk of Ovarian Malignancy Algorithm, Overa) are biomarker-driven considerations that are presented. Integration of biomarkers into ovarian cancer diagnostics and screening are presented in conjunction with ultrasound. Consideration is given to the serial application of both biomarkers and ultrasound, as well as morphology-based indices. Attempts are made to foresee how individualized molecular signatures may be able to both provide an alert of the potential for ovarian cancer and to provide molecular treatments tailored to a personalized genetic signature. In the future, an annual pelvic ultrasound and a comprehensive serum biomarker screening/diagnostic panel may replace the much maligned bimanual examination as part of the annual gynecologic examination. Taken together, it is likely that a new medical specialty for screening and early diagnostics will emerge for physicians and epidemiologists, a field of study that is independent of patient gender, organ, or the subspecialties of today.

Original languageEnglish
Article number14
Issue number1
StatePublished - Mar 2017

Bibliographical note

Publisher Copyright:
© 2017 by the author. Licensee MDPI, Basel, Switzerland.


  • Biomarkers
  • Ovarian cancer
  • Ovarian tumor biomarkers
  • Serial ultrasound
  • Ultrasound

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come'. Together they form a unique fingerprint.

Cite this